September 8, 2023 05:21 AM EDTUpdated September 12, 08:09 AM
R&D
Pharma
In Focus

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Reynald Castañeda

Deputy Editor

Back in 2020, be­fore semaglu­tide be­came a house­hold name — be­fore it was even ap­proved to treat obe­si­ty — No­vo Nordisk qui­et­ly notched a break­through ther­a­py des­ig­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times